Table 2 Baseline values of outcome measures
| Â | Fluvoxamine (n = 17) | Placebo (n = 16) | P-value |
|---|---|---|---|
VAS Fatigue | 7.40 | 7.45 | 0.91 |
VAS Pruritus | 3.50 | 1.15 | 0.33 |
Beck Depression Inventory | 11.0 | 10.5 | 0.45 |
FFSS | |||
   Physical Domain | 24.0 | 16.5 | 0.25 |
   Cognitive Domain | 15.0 | 9.0 | 0.04 |
   Social Domain | 37.0 | 22.5 | 0.04 |
MFI | |||
   General Fatigue | 18.0 | 17.5 | 0.78 |
   Physical Fatigue | 16.0 | 14.0 | 0.22 |
   Reduction in Activity | 15.0 | 13.0 | 0.30 |
   Reduction in Motivation | 13.0 | 10.0 | 0.17 |
   Mental Fatigue | 13.0 | 13.0 | 0.90 |
SF-36 | |||
   Physical Functioning | 65.0 | 70.0 | 0.47 |
   Role Functioning Physical | 25.0 | 25.0 | 0.35 |
   Bodily Pain | 62.0 | 62.0 | 0.55 |
   General Health | 40.0 | 35.0 | 0.63 |
   Vitality | 45.0 | 40.0 | 0.64 |
   Social Functioning | 62.5 | 62.5 | 0.34 |
   Role Emotional Functioning | 100.0 | 66.7 | 0.46 |
   Mental Health | 56.0 | 60.0 | 0.28 |
   Reported Health Transition | 4.0 | 4.0 | 1.00 |